AARA STORY TELLERS NEEDED!

The Alliance is seeking new stories about our members who have benefitted or will benefit from the prescription drug provisions of the Inflation Reduction Act. We have funds available for \$300 per story for up to 30 stories nationally which will be granted to state Alliances on a first come, first served basis. In order to receive the grant award for these stories, each person such must:

- Be a Medicare recipient
- Be an Alliance member (either national or state) or be willing to join for \$10 if not from a participating union
- Not have had their IRA story previously shared with the national Alliance
- Benefit in some way from the Inflation Reduction Act's prescription drug provisions, such as:
 - Receive lower-cost insulin due to the \$35 out-of-pocket cap
 - Have high-cost prescription drugs and will receive a price reduction in 2025 when the \$2,000 out-of-pocket cap is implemented
 - Take one of the ten drugs that will be subject to prescription drug price negotiation:

Drug Name	Commonly Treated Conditions
Eliquis	Prevention and treatment of blood clots
Jardiance	Diabetes; Heart failure
Xarelto	Prevention and treatment of blood clots; Reduction of risk for
	patients with coronary or peripheral artery disease
Januvia	Diabetes
Farxiga	Diabetes; Heart failure; Chronic kidney disease
Entresto	Heart failure
Enbrel	Rheumatoid arthritis; Psoriasis; Psoriatic arthritis
Imbruvica	Blood cancers
Stelara	Psoriasis; Psoriatic arthritis; Crohn's disease; Ulcerative colitis
Fiasp; Fiasp FlexTouch; Fias NovoLog; NovoLog FlexPen;	Diabetes

- Were able to get a free vaccine such as shingles, polio booster, or tdap (diphtheria, tetanus and pertussis) this year that they otherwise would not have due to it being cost-prohibitive
- Be willing to share their story publicly and sign a media release
- Have their stories vetted by members of the Alliance Communication Team.

If you are willing to share your story please contact AARA Executive Director Dora Vasquez at 602.689.8048 or Retirees@azaflcio.org no later than Friday, September 14, 2023